Company news

Allogene Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021

April 26, 2021

Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma

April 20, 2021

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

April 18, 2021

Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

April 11, 2021

Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting

April 9, 2021

Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

February 24, 2021

Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine

January 25, 2021

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma

December 22, 2020

Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies

December 14, 2020

Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology

December 6, 2020

Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020

December 1, 2020

Allogene Therapeutics Reports Third Quarter 2020 Financial Results

November 3, 2020

Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology

November 3, 2020

Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020

October 26, 2020

Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)

October 14, 2020

Allogene Therapeutics Reports Second Quarter 2020 Financial Results

August 4, 2020

Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board

July 6, 2020

Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize

June 30, 2020

Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia

June 21, 2020

Allogene Therapeutics Announces June 2020 Virtual Investor Conference Participation

June 2, 2020

Allogene Therapeutics Announces Commencement of Public Offering of Common Stock

May 31, 2020

Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting

May 28, 2020

Allogene Therapeutics Announces Webinar to Review Initial ALLO-501 Phase 1 Data on May 29, 2020

May 25, 2020

Allogene Therapeutics Reports First Quarter 2020 Financial Results

May 5, 2020

Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

April 28, 2020

Allogene Therapeutics to Report First Quarter 2020 Financial Results on May 6, 2020

April 26, 2020

Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

February 26, 2020

Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule

February 5, 2020

Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma

January 12, 2020

Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule

November 10, 2019

Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting

November 5, 2019

Allogene Therapeutics Reports Third Quarter 2019 Financial Results

November 4, 2019

Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma

April 14, 2019

Allogene Therapeutics Announces April 2019 Investor Conference Schedule

April 2, 2019

← Newer news releases

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.